[Antipsychotics--clever choices].
Ek
Mats
M
mats.a.ek@sll.se
Lindefors
Nils
N
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D016527:Drug Costs; D019317:Evidence-Based Medicine; D018149:Glucose Intolerance / Q000139:chemically induced; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008055:Lipids / Q000097:blood; D000077152:Olanzapine; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine; D006220:Haloperidol; D008055:Lipids; D000077152:Olanzapine; D010546:Perphenazine; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors